Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543817 | 0.92 | CD274 (0.92) | CD274TSHRALDH1A1KDM4EHTR1A | |
| SCHEMBL763452 | 0.86 | HTT (0.78) | CD274TSHRALDH1A1SMN1; SMN2KDM4E | |
| Eprobemide SCHEMBL570896 | 0.86 | ALDH1A1 (0.85) | CD274TSHRALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9199198 | 0.86 | LMNA (0.67) | CD274TSHRALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1382764 | 0.86 | SMN1; SMN2 (0.95) | CD274TSHRALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12089972 | 0.86 | LMNA (0.83) | CD274TSHRALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2249600 | 0.85 | TSHR (0.74) | CD274TSHRALDH1A1SMN1; SMN2KDM4E | |
| Eprobemide SCHEMBL10495496 | 0.85 | ALDH1A1 (0.82) | CD274TSHRALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL22823029 | 0.85 | SMN1; SMN2 (0.70) | CD274TSHRALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3324927 | 0.85 | TSHR (0.70) | CD274TSHRALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689652-B | Fused heterocyclic derivative, preparation method and medical application thereof | 北京诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-20200390909-A1 | DRUG FRAGMENT IMAGING AGENT CONJUGATES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-12-17 | — | — | US | disclosed |
| WO-2019173483-A1 | DRUG FRAGMENT IMAGING AGENT CONJUGATES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| CN-109689652-A | Fused heterocycle derivative, preparation method and its application medically | 北京诺诚健华医药科技有限公司 | 2019-04-26 | — | — | CN | disclosed |
| EP-2343303-A1 | PI3-kinase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | IDO1, IDO2, INMT | CD274 1225/4885TSHR 4220/4885ALDH1A1 890/4885 |
| US-20200390909-A1 | DRUG FRAGMENT IMAGING AGENT CONJUGATES | FUCA1, SI, FOLH1 | CD274 2270/4885TSHR 3084/4885ALDH1A1 539/4885 |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | IDO1, IDO2, INMT | CD274 1225/4885TSHR 4220/4885ALDH1A1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.